Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to CSF-1R Inhibitor, EI-1071 for the Treatment of Idiopathic Pulmonary Fibrosis

The U.S. FDA has granted Orphan Drug Designation to our colony stimulating factor 1 receptor inhibitor, EI-1071 for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic interstitial lung disease characterized by tissue fibrosis and progressive decline in lung function. Currently, there is no cure for IPF and only two approved drugs slow but do not halt disease progression. On average, patients with IPF continue to live for only three to five more years once diagnosed with IPF. Read our press release here